Welcome to our dedicated page for Orgenesis news (Ticker: ORGS), a resource for investors and traders seeking the latest updates and insights on Orgenesis stock.
Orgenesis Inc (ORGS) is a global biotechnology leader pioneering decentralized cell and gene therapy manufacturing. This page provides investors and industry professionals with centralized access to official press releases, clinical trial updates, and strategic partnership announcements.
Track the latest developments in ORGS's innovative platforms, including therapeutic exosome production, automated GMP processes, and modular cleanroom deployments. Our curated news collection ensures timely updates on regulatory milestones, research breakthroughs, and operational expansions.
Key coverage areas: clinical trial progress, manufacturing partnerships, technology licensing agreements, and regulatory submissions. Bookmark this page for direct access to verified information about ORGS's advancements in immuno-oncology and regenerative medicine.
Rhea-AI Summary
Germfree and Orgenesis Inc. announce a strategic partnership to advance cell and gene therapy production. The collaboration aims to reduce production costs, increase accessibility to treatments, and revolutionize the bio-manufacturing industry. Orgenesis will co-market its Octomera platform with Germfree, enhancing market expansion opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.12%
Tags
-
Rhea-AI Summary
Orgenesis Inc. (ORGS) CEO, Vered Caplan, to present at Bioprocessing Summit Europe on overcoming conventional CGT processing challenges with POCare solutions. The conference aims to advance manufacturing and quality control of biological and genetic therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.39%
Tags
-
Rhea-AI Summary
Orgenesis Inc. has been awarded a €1.5 million grant from the Walloon government in Belgium for its EXOFASTTRACK project, focusing on manufacturing therapeutic exosomes. The project aims to accelerate the development of multiple therapeutic exosomes for clinical evaluation, potentially reducing production costs and promoting accessibility to life-saving therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
Rhea-AI Summary
Orgenesis Inc. announced a private placement agreement with accredited investors for the sale of shares and warrants, expecting to raise around $2.3 million. The deal includes 2,272,719 shares of common stock and corresponding warrants at different exercise prices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.24%
Tags
-
Rhea-AI Summary
Orgenesis Inc. (ORGS) announces a €2.0 million grant from the Walloon Government in Belgium for AI monitoring of decentralized ATMP manufacturing. The project aims to enhance the production of advanced therapy medicinal products through AI-based approaches. The grant is part of a larger initiative with an €81 million budget over three years to drive technological innovation in the ATMP sector, creating jobs and fostering partnerships. Orgenesis plans to utilize the grant to accelerate the placement of a CAR-T dedicated facility in Belgium, making CAR-T therapies more affordable in the region.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
-
Rhea-AI Summary
Orgenesis Inc. (ORGS) announced the acquisition of Metalmark's 25% stake in Octomera LLC, giving Orgenesis 100% ownership of the cell processing services subsidiary. Metalmark will receive a 5% royalty of Octomera's net revenue for 2025-2027 and a portion of proceeds in case of a change of control in the next 10 years. CEO Vered Caplan highlighted the industry's need for decentralized cell therapy and the support from FDA and EMEA regulators. The company's focus on developing proprietary therapeutics and advancing oncology therapeutics was emphasized. Newly appointed CFO Victor Miller expressed confidence in the company's expertise and portfolio, thanking Metalmark for their support. Public updates on the company's therapeutics and technologies are expected throughout 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
Rhea-AI Summary
Orgenesis Inc. (NASDAQ: ORGS) ranked 171 on the Deloitte Technology Fast 500™, recognizing the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America. CEO Vered Caplan highlighted the company's decentralized approach to manufacturing advanced cell and gene therapies, aiming to lower costs, streamline logistics, and expand capacity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
-
Rhea-AI Summary
Orgenesis Inc. (NASDAQ: ORGS) provided a business update for the third quarter ended September 30, 2023, highlighting the advances in the rollout of its POCare Platform and POCare Therapies. The CEO, Vered Caplan, emphasized the expansion of partnerships with California Davis and CGT Global for streamlined production and accelerated research and clinical trials. The Company's focus on advancing cell and gene therapies across the U.S., Europe, the Middle East, and other regions is evident in its efforts to build a decentralized network and infrastructure through Octomera, aiming to meet the growing demand for these advanced therapeutic services. Additionally, Orgenesis is advancing its therapeutic pipeline, spanning multiple clinical programs in immuno-oncology, anti-viral, metabolic/autoimmune diseases, and tissue regeneration, while leveraging government grants and funding from regional partners.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
-
Rhea-AI Summary
Orgenesis Inc. (ORGS) announces a registered direct offering to sell $1.1 million of common stock and warrants to a single institutional investor, with a combined effective purchase price of $0.78 per share. Titan Partners Group is the sole placement agent for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.26%
Tags
News
Rhea-AI Summary
Orgenesis Inc. announces continued progression of its Point of Care (POCare) network and infrastructure for advanced therapeutic services and facilities. The company's subsidiary, Octomera, has been confirmed as an industrial partner to the University of California Davis, following a recent California Institute of Regenerative Medicine (CIRM) grant. The collaboration aims to standardize Good Manufacturing Practice (GMP) manufacturing capabilities and create a network to harmonize operations for cell and gene therapy manufacturing. UC Davis and Orgenesis are interested in expanding the point of care (POC) network model to decentralize medical innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
Orgenesis Inc
Nasdaq:ORGS
ORGS Rankings
ORGS Stock Data
7.92M
3.76M
20.14%
0.95%
1.18%
Biotechnology
Pharmaceutical Preparations
United States
GERMANTOWN